Fin Maverick
QuarksCourses
PartnershipsShowdown
Log inSign up
Interview tracksAll
1Investment Banking
Question bankPuzzlesCase studies
2Equity Research
Question bankPuzzlesCase studies
3Venture Capital
Question bankPuzzlesCase studies
4Private Equity
Question bankPuzzlesCase studies
5Hedge Funds
Question bankPuzzlesCase studies
6Quant
Question bankPuzzlesCase studies
7Financial Analysis
Question bankPuzzlesCase studies
8Private Wealth Management
Question bankPuzzlesCase studies
9Debt Capital Markets
Question bankPuzzlesCase studies
10Risk Management
Question bankPuzzlesCase studies
11Derivatives Foundation
Question bankPuzzlesCase studies
12Portfolio Management
Question bankPuzzlesCase studies
13Mutual Fund Mastery
Question bankPuzzlesCase studies

Equity Research case studies, worked step by step

Cases
100
Traced to a firm
30
Topics
12
Hard
30
Topic
All topicsStock pitch15Earnings and results9Forecasting and modelling10DCF and intrinsic value9Relative valuation7Financials6Sector economics9Forensic accounting9Industry structure and moats7Macro and commodity sensitivity7Capital allocation and corporate actions7Buy-side portfolio judgement5
Level
AnyWarm upCoreHard
Source
AnyReported at a firmStandard
Showing 1–7 of 7 · filtered from 100Clear filters
  1. 011Serovan Pharma holds Rs 4,000 crore of net cash and trades at 25x earnings. Rank three uses of the cash: a buyback, an acquisition at 15x EBIT of a business earning a 12% return on capital, or a special dividend.Capital allocation and corporate actionsCoreSell-side equity researchBuy-side equity research→
  2. 021Hemvara Utilities pays out 90% of its profit as dividends while free cash flow is only 70% of profit. How is the gap funded, and is the dividend safe?Capital allocation and corporate actionsWarm upLong-only asset managementIndian brokerage research→
  3. 036How would you IPO a school? Vidhyora Schools has EBITDA of Rs 150 crore and net debt of Rs 200 crore; at 20x EV/EBITDA it raises Rs 600 crore of new money and the promoter sells Rs 400 crore. Work out the post-money value, the dilution and the free float.Capital allocation and corporate actionsCoreWMWellington ManagementBoston · 2024→
  4. 047Pallanza Hospitals raises Rs 1,000 crore through a placement at a 5% discount, adding about 8.8% to its share count, to build three hospitals that break even in year three. When does the deal start adding to EPS?Capital allocation and corporate actionsCoreSell-side equity researchIndian brokerage research→
  5. 061Aurevik Foods buys Zestora Naturals, a direct to consumer brand, for 6x sales. Zestora's operating profit is small but growing 30% a year. How many years until the deal earns Aurevik's 12% cost of capital?Capital allocation and corporate actionsHardBuy-side equity researchHedge fund long/short→
  6. 086A group is demerging its consumer arm, which peers value at 30x EBITDA, from its chemicals arm, valued at 12x. The group trades at 14x. How much value could the split unlock?Capital allocation and corporate actionsHardSell-side equity researchIndian brokerage research→
  7. 097A steel company plans to double capacity for Rs 8,000 crore against a market value of Rs 12,000 crore. The new plant's mid-cycle ROCE is 11% against a 12% cost of capital. Should the market welcome it?Capital allocation and corporate actionsCoreLong-only asset managementSell-side equity research→

Company names and figures are illustrative.

Fin Maverick

Finance education that ends in a job, not a certificate that gathers dust. Built for young India.

LEARN
CalculatorsFrameworksComparisonsInterview RoadmapsShowdown
RESOURCES
All CoursesFree CoursesBootcampsNISMQuarksAI for Finance
COMPANY
AboutJob openingPartnership
LEGAL
Privacy PolicyTerms & ConditionsContent LicenseReturn & Refund Policy
© 2026 FIN MAVERICK / BUILT FOR INDIA.DO FINANCE, DO NOT JUST READ ABOUT IT.